Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALERT: Alternating Eribulin and Hormonal Therapy in Pretreated ER-positive Breast Cancer
2014-004112-11Phase 2Terminated
- Sponsor
- Imperial College London
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in breast cancer, sponsored by Imperial College London. Primary endpoint: Progression-free survival. Started Apr 2015; status: terminated.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-004112-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004112-11.